Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, i2O Therapeutics is raising $42,032,225.00 in new funding. Sources indicate as part of senior management President, Ravi Srinivasan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About i2O Therapeutics
i2o Therapeutics is pioneering the use of Ionic Liquids (ILs) for therapeutic development. i2os wholly-owned pipeline consists of first-in-class and best-in-class transformative oral biologics with improved clinical benefits and a superior safety profile over current standard of care. With an initial focus on metabolic and inflammatory diseases, i2o is delivering on the promise of oral biologics considered the holy grail biologic opportunity by the pharmaceutical industry. By accessing technology developed at Harvard University, we are redefining the patient experience by combining the convenience of oral medication with the superior clinical benefits of biologics. We do this by pairing a world-renowned team of chemical engineers, bioengineers, and biologists with experienced industry veterans having developed and launched over 15 blockbuster products.

To learn more about i2O Therapeutics, visit http://i2obio.com/

Contact:
Ravi Srinivasan, President
617-863-3650
https://www.linkedin.com/in/ravisrinivasan3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved